The discovery of crucial misexpressed genes in lung cancer allows a better understanding about the tumor microenvironment and the biomarkers that are a genetic fingerprint of this cancer. These biomarkers provide relevant knowledge to start the development of targeted therapies, overcoming the side effects and the development of resistances associated with the conventional treatments. Gene therapy and RNAi-based drugs are pointed out as promising and exciting new approaches to treat lung cancer.